{"id":"W2947759305","doi":"10.1200/jco.2019.37.15_suppl.9504","title":"United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Discontinuation; Ipilimumab; Adverse effect; Placebo; Adjuvant; Hazard ratio; Randomized controlled trial; Intention-to-treat analysis; Oncology; Gastroenterology; Surgery; Cancer; Confidence interval; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004064388,0.001596755,0.001288256,0.0005932619,0.0004280409,0.0007888437,0.001014663,0.001481269,0.009976569],"category_scores_gemma":[0.001522699,0.000748992,0.00140104,0.0004930045,0.000817669,0.0007065204,0.0005356011,0.003367888,0.001782518],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008461342,"about_ca_system_score_gemma":0.001550403,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009550715,"about_ca_topic_score_gemma":0.002933484,"domain_scores_codex":[0.9990366,0.0006934475,0.00004110231,0.00008482278,0.00006132099,0.00008284095],"domain_scores_gemma":[0.999215,0.0001683502,0.0001941713,0.00006545253,0.0000444973,0.0003124737],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9274067,0.02377786,0.002731152,0.0006924819,0.001283994,0.00008190455,0.00008970235,0.00058178,0.007260405,0.0004193091,0.006662563,0.02901215],"study_design_scores_gemma":[0.9255773,0.06605899,0.003306493,0.00005101481,0.0004998524,0.00007769383,0.00002559026,0.0004481227,0.000839171,0.0001537264,0.002945963,0.00001608961],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9565325,0.006091657,0.001573995,0.002108614,0.000793206,0.015817,0.008081375,0.0002708574,0.00873086],"genre_scores_gemma":[0.9520124,0.004038799,0.004673858,0.004366139,0.0005458494,0.01536554,0.006877662,0.00008937955,0.01203027],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009976569,"threshold_uncertainty_score":0.03337497,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1243248276908649,"score_gpt":0.4960098934329372,"score_spread":0.3716850657420723,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}